RxDoctor Payments Data

Marta Jaramillo, PA

Physician Assistant · Philadelphia, PANPI 1548247414

Payments from drug & device makers

$1,094in general payments, 2019–2025

Across 29 payments — averaging $37.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$270
  • Sanofi-aventis U.S. LLC$236
  • GSK$169
  • AstraZeneca$139
  • AbbVie$112
  • Johnson & Johnson$87
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$1,094100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,094 in reported general payments places this provider in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,807
Medicare patients
47
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide119$120,411
JardianceEmpagliflozin81$63,080
JanuviaSitagliptin Phosphate37$28,389
EliquisApixaban34$25,140
OzempicSemaglutide25$23,700
Breo ElliptaFluticasone/Vilanterol45$17,657
FarxigaDapagliflozin Propanediol22$17,266
Albuterol Sulfate HfaAlbuterol Sulfate373$11,204
Lantus SolostarInsulin Glargine,hum.Rec.Anlog111$10,863
XareltoRivaroxaban14$9,843
LinzessLinaclotide18$9,360
MyrbetriqMirabegron20$8,932
SymbicortBudesonide/Formoterol Fumarate39$8,359
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$7,021
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate45$6,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$139$25,62561 claims
GSKBreo Ellipta, Anoro Ellipta$169$23,74658 claims
Novo NordiskOzempic$270$23,70025 claims
Johnson & JohnsonXarelto$87$9,84314 claims
AbbVieLinzess$112$9,36018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →